Access to Information Requests Completed - April 2012

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

Completed Requests

For the month of April 2012

Request #	Summary of Requests	Status of Completed Request	Number of Pages Disclosed
A-2010-00641	Information regarding the product Ketorolac Tromethamine Injection, USP, DIN 02244947 by Pharmaceutical Partners of Canada Inc.	Disclosed in part	33
A-2010-00806	All documents pertaining to the Brazilian Blowout hair smoothing treatment. (Jan 1, 2005 to Oct 28, 2010).	Disclosed in part	496
A-2010-00874	Information regarding the product Symbicort Turbuhaler, DINs 02245385 and 02245386 by Astrazeneca Canada Inc.	Disclosed in part	2,401
A-2011-00129	Information regarding the product Monensin Premix, DIN 02243232 by Bio Agri Mix LP.	Disclosed in part	834
A-2011-00332	All Serious Adverse Drug Reaction Reporting, Annual Summary Report and Case Report, and Issue-related Summary Reports for the product marked DIN 02019698 and 02019736.	Disclosed in part	47
A-2011-00531	AERs for the product Tylenol. Report numbers: 000307916, 000309186, 000310725, 000310897, 000310898, 000310900, 000310904, 000310910, 000310911 and 000310912.	Disclosed in part	82
A-2011-00627	AERs for the product INTEGRILIN. Report numbers: 000197706, 000301062, 000306129 and 000309189.	Disclosed in part	56
A-2011-00945	All Marihuana Medical Access Regulations (MMAR) applications. (Jan 1, 2007 to Oct 31, 2011).	Disclosed in part	1,120
A-2011-01004	All documents related to Institute of Medicine's 'front-of-package' Phase 2 report. (Oct 1, 2011 to Oct 28. 2011).	Disclosed in part	79
A-2011-01154	Correspondence relating to the issue of the use of enzymes in natural health products. (Jan 1, 2008 to Feb 29, 2010).	Disclosed in part	109
A-2011-01217	Any clinical trial application submitted to Health Canada for a REMICADE study known as ANTI-TNF TRIAL IN LONG TERM TREATMENT OF MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE, this study also known as ACCENT I.	Disclosed in part	216
A-2011-01327	AERs for the product Canesten. Report numbers: 000373639, 000375848 and 000377062.	Disclosed in part	7
A-2011-01359	Information regarding the products Exelon Patch 5 and Exelon Patch 10, DINs 02302845 by Novartis Pharmaceuticals Canada Inc.	Disclosed in part	201
A-2011-01369	Information regarding the product Extra Strength Mucous Relief Chest, DIN 02353571 by Arrow OTC Company.	Disclosed in part	61
A-2011-01386	AERs. Report numbers: 000370015, 000378013, 000376271, 000373448 and 000375689.	Disclosed in part	19
A-2011-01392	Drug applications and approvals submitted to Health Canada from the Children's Hospital of Eastern Ontario (CHEO) for the drug Sorafenib (Nexavar) by Bayer on a compassionate basis. AERs from Sep 1, 2010 to Jan 18, 2012.	Disclosed in part	50
A-2011-01407	Briefing material prepared for the health minister from December 1, 2011 to January 24, 2012.	Disclosed in part	114
A-2011-01577	All contracts processed by this institution in the National Capital Region for the procurement of Temporary Help Services during the period of January 2012.	Disclosed in part	8
A-2011-01607	The annual base salary, extra-duty, overtime pay and bonus performance pay for the fiscal year 2010/11 for each driver to the Minister.	Disclosed in part	14
A-2011-01610	AER for the active ingredient Perindopril 4 mg/Indapamide 1.25mg. Report number: 000355700.	Disclosed in part	6
A-2011-01612	AER for the product Gliclazide MR. Report number: 000368233.	Disclosed in part	1
A-2011-01619	All contracts processed by this institution in the National Capital Region for the procurement of Temporary Help Services during the period of February 2012.	Disclosed in part	11
A-2011-01638	All information regarding the consensus workshop on ultrasound imaging used to diagnose blocked veins from September 2011.	No records exist	0
A-2011-01644	AER. Report numbers: 000379845 and 000374866.	Disclosed in part	5
A-2011-01646	A listing of the Access to Information requests submitted to Health Canada. (Feb 1, 2012 to Feb 29, 2012).	Disclosed in part	30
A-2011-01673	All final reports or briefing notes such as signal assessments, causality assessments, health hazard evaluations or any memo which assesses maintenance concerns with defibrillators and issues that have arisen with routine maintenance or lack thereof. (Jan 1, 2007 to Feb 1, 2012).	No records exist	0
A-2011-01682	Reviewer's notes and approval summary documents for the following Pfizer product: Fragmin 7500IU (Anti-Xa) /0.3ml (DIN: 02352648). Generic name is dalteparin sodium.	No records exist	0
A-2011-01683	Reviewer's notes and approval summary documents for the following Pfizer product: Fragmin 25000IU (Anti-Xa) /ML (DIN: 02231171). Generic name is dalteparin sodium.	No records exist	0
A-2011-01684	Reviewer's notes and approval summary documents for the following Pfizer product: Fragmin 10,000IU (Anti-Xa) 0.4ml (DIN: 02352656). Generic name is dalteparin sodium.	No records exist	0
A-2011-01686	Request the reviewer's notes and approval summary documents for the following Pfizer product: Fragmin 10,000IU (Anti-Xa) /ml (DIN: 02132664). The generic name of this product is dalteparin sodium)	No records exist	0
A-2011-01687	All documents related to cell phones causing various forms of cancer.	No records exist	0
A-2011-01689	Reviewer's notes and approval summary documents for the following Pfizer product: Fragmin 12500IU (ANTI-XA) /0.5ml (DIN: 02352664). Generic name is dalteparin sodium.	No records exist	0
A-2011-01692	Reviewer's notes and approval summary documents for the following Pfizer product: Fragmin 15000IU (ANTI-XA) /0.6ml (DIN: 02352672). Generic name is dalteparin sodium.	No records exist	0
A-2011-01694	Reviewer's notes and approval summary documents for the following Pfizer product: Fragmin 18000IU (ANTI-XA) /0.72ml (DIN: 02352680). Generic name is dalteparin sodium.	No records exist	0
A-2011-01698	Reviewer's notes and approval summary documents for the following Pfizer product: Fragmin 25000IU (ANTI-XA) /ml (DIN: 02231171). Generic name is dalteparin sodium.	No records exist	0
A-2011-01701	Reviewer's notes and approval summary documents for the following Pfizer product: Fragmin 2500IU (ANTI-XA) /0.2ml (DIN: 02132621). Generic name is dalteparin sodium.	No records exist	0
A-2011-01706	Reviewer's notes and approval summary documents for the following Pfizer product: Fragmin 5000IU (ANTI-XA) /0.2ml (DIN: 02132648). Generic name is dalteparin sodium.	No records exist	0
A-2011-01707	Copies of blank patient consent forms received or obtained by Assisted Human Reproduction Canada (AHRC) from each of the in vitro fertilization (IVF) clinics across Canada. (Dec 1, 2007 to Mar 20, 2012).	No records exist	0
A-2011-01721	ADRs regarding two cases where the patients died while possibly receiving DEXTROMETHORPHAN. The report indicating these deaths was dated March 2, 2012 and was posted to the Coroner's Office of Québec's website.	All disclosed	4
A-2011-01731	Health Canada's Standard Operating Procedures or internal policies associated with; 1. the assignment of Central Registry File Numbers and Control Numbers for submissions to the Therapeutic Products Directorate 2. Administrative DIN submissions including those filed as per the Changes in Manufacture's Name and/or Product Name.	All disclosed	21
A-2011-01738	All documents related to bioterror and biological or chemical weapons. (Jan 1, 2009 to Mar 13, 2012).	No records exist	0
A-2011-01745	A list of all records related to overpayments or suspected overpayments to service providers through the Non-Insured Health Benefits Program. (Jan 1, 2009 to Mar 27, 2012).	All disclosed	7
A-2011-01751	AER. Report number: 000355637.	Disclosed in part	3
A-2011-01752	All documents concerning the development and/or intention of the committee outlined under Section 67. (1) of the Canada Consumer Product Safety Act.	All disclosed	3
A-2011-01758	Total number in each pay classification for the following: North Bay & Sudbury full time indeterminate and term employees. March 1 2012 & March 1 2000.	All disclosed	1
A-2012-00033	A listing of the Access to Information requests submitted to Health Canada. (Mar 1, 2012 to Mar 31, 2012).	Disclosed in part	13